Omada Health (NASDAQ:OMDA) Now Covered by Barclays

by · The Cerbat Gem

Barclays assumed coverage on shares of Omada Health (NASDAQ:OMDA – Free Report) in a report released on Tuesday morning, Marketbeat.com reports. The firm issued an overweight rating and a $21.00 price objective on the stock.

A number of other research analysts have also issued reports on OMDA. The Goldman Sachs Group started coverage on Omada Health in a report on Tuesday. They set a “buy” rating and a $29.00 target price on the stock. Needham & Company LLC initiated coverage on Omada Health in a report on Tuesday. They issued a “buy” rating and a $23.00 target price for the company. Wall Street Zen upgraded shares of Omada Health to a “hold” rating in a report on Monday, June 16th. Finally, Canaccord Genuity Group assumed coverage on Omada Health in a research report on Tuesday. They issued a “buy” rating and a $27.00 target price on the stock. One investment analyst has rated the stock with a hold rating and seven have issued a buy rating to the stock. According to MarketBeat.com, Omada Health presently has an average rating of “Moderate Buy” and a consensus price target of $23.57.

Get Our Latest Stock Report on Omada Health

Omada Health Stock Up 2.9%

Shares of OMDA opened at $18.63 on Tuesday. Omada Health has a 52-week low of $14.14 and a 52-week high of $28.40.

About Omada Health

(Get Free Report)

Omada’s mission is to bend the curve. Our hope is that, one day, tomorrow’s epidemiologists will notice a bend in disease curves, wonder what might be happening, and conclude that part of that impact has been Omada. As part of that mission, we strive to inspire and enable people to make lasting health changes on their own terms.

See Also